Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

20260 citationsJournal Articlediamond Open Access

Authors

Lebrikizumab demonstrated off-therapy maintenance of response in an AD patient subset for at least 38 weeks post-discontinuation.

Published in: Journal of Dermatological Treatment

Volume 37, Issue 1, pp. 2636417-2636417

Field-Weighted Citation Impact: 0.00